IRVING, Texas, Feb. 16, 2010 (GLOBE NEWSWIRE) -- Caris Life Sciences (Caris®) -- a leading provider of integrated anatomic pathology and oncology testing services, including molecular profiling and hematopathology -- today announced the launch of The Caris RegistrySM, a biomarker-driven repository to help predict clinical benefit and patients' responses to cancer therapy including chemotherapy, immunotherapy and biological therapy.
"The Caris Registry provides a centralized, real-time data repository through which treating physicians can share and expand their understanding of personalized treatment options for their patients," said Alan Wright, Senior Vice President of Strategy at Caris. "Equipped with information obtained through the Registry, physicians will have significant opportunities to improve outcomes for patients."
The Caris Registry will be comprised of profiling information and clinical outcomes from patients using the Target Now® series of molecular profiling services. Target Now® is an oncology testing service offered exclusively through Caris that utilizes cutting-edge molecular profiling techniques to identify key characteristics about a patient's tumor as an aid to the treating oncologist.
"Our goal is to make The Caris Registry the most clinically valuable oncology registry in the nation," said David D. Halbert, Chairman and CEO of Caris Life Sciences. "Caris' significant investment in the initiation, development and support of this cutting-edge program further solidifies our leadership position as the trusted provider of precision healthcare solutions."
Caris anticipates that the Registry will provide vital information to the government, insurers and medical providers by providing a high-volume of real-time, catalogued outcome information for analysis. Caris also anticipates that collaboration with these organizations will result in the advancement of key drug-development strategies, future healthcare policies, prospective clinically relevant research trials, publications, and posters.
For more information on how clinics, doctors and researchers may be able to participate in the Caris Registry, please contact carisregistry@carisls.com
About Caris Life Sciences
Caris Life Sciences is a U.S. based biosciences company specializing in the development and commercialization of clinically-validated molecular diagnostics and anatomic pathology services primarily in the fields of oncology, dermatopathology, hematopathology and gastrointestinal pathology. The company provides academic-caliber medical consults through its industry-leading team of subspecialty fellowships and expert-trained pathologists in gastrointestinal and liver pathology, dermatopathology and hematopathology. Caris Life Sciences also offers advanced molecular analyses of patient samples through prognostic testing services and genomic and proteomic profiling to assist physicians in their treatment of cancer and other complex diseases. Biopsies from thousands of patients are received daily for analysis by Caris from physicians. Formed in 1996, the company is headquartered in Irving, Texas and operates four laboratories: Irving, Texas; Phoenix, Arizona (two sites) and Newton, Massachusetts. Additional information is available at www.carislifesciences.com.
About Target Now®
Target Now® is a commercially available oncology testing service, offered exclusively through Caris Life Sciences. Target Now® utilizes cutting-edge molecular profiling techniques, including DNA microarray, immunohistochemical (IHC) analysis, fluorescent in-situ hybridization (FISH), gene sequencing, and DNA sequencing to provide individualized molecular information about a patient's tumor as an aid to the treating oncologist. Patients who have had their tumors profiled utilizing Caris's Target Now® program and whose criteria match those necessary to participate, may be invited through their physician to enroll in the registry.